Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051051 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
NCT00051051 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 168 participants.
The verdict
NCT00051051, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
Study Summary
CI-1033 is an experimental drug that acts as an inhibitor of erbB (EGFR) receptors, which may be involved in tumor growth. The primary objective of this study is to assess the antitumor activity of CI-1033 in patients with metastatic breast cancer. Patients with histologically confirmed metastatic (Stage IV) breast cancer and who have received no more than 2 prior cytotoxic chemotherapy regimens are eligible for this study. CI-1033 is administered orally. Patients are required to have blood tests periodically while receiving treatment and will be closely monitored throughout the study for possible side effects and response to treatment. Patients may not have received any prior treatment with other agents that target erbB receptors, including Herceptin (trastuzumab) or Iressa (gefitinib).
Interventions
- DRUG CI-1033
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2002-12 |
| Est. Completion | 2005-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00051051
The ClinicalTrials.gov registry entry for NCT00051051 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CI-1033 is the first listed.
NCT00051051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00051051 about?
NCT00051051 is a clinical study titled "A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer". CI-1033 is an experimental drug that acts as an inhibitor of erbB (EGFR) receptors, which may be involved in tumor growth. The primary objective of this study is to assess the antitumor activity of CI-1033 in patients with metastatic breast cancer. Patients with histologically confirmed metastatic (...
What is the current status of trial NCT00051051?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2002-12. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00051051?
The interventions under investigation include: CI-1033 (DRUG).
Who is sponsoring clinical trial NCT00051051?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.